Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.

Descrizione del progetto

Un trattamento rivoluzionario per le cefalee croniche

La cefalea a grappolo cronica e l’emicrania sono condizioni debilitanti che colpiscono milioni di persone in tutto il mondo, causando intenso dolore e sofferenza. Per molti pazienti, gli attuali trattamenti farmacologici non forniscono un sollievo sufficiente. Salvia BioElectronics B.V. ha sviluppato un impianto innovativo, sottile come carta, progettato per ridurre la frequenza e l’intensità degli attacchi di mal di testa. L’impianto minimamente invasivo di Salvia è stato progettato in modo unico per l’uso sicuro nella regione cranio-facciale. Il progetto ReLife, finanziato dal CEI, intende accelerare la disponibilità della nuova terapia per la cefalea a grappolo, sostenendo così un impatto trasformativo nel mercato dell’emicrania, di dimensioni ben più ampie.

Obiettivo

Chronic cluster headache and chronic migraine pose a significant challenge for patients and neurologists worldwide. Approx. 48-64% of the patients experience only limited relief from drug-based treatments, they are drug-refractory. Salvia BioElectronics B.V. developed PRIMUS, an innovative peripheral nerve modulator to treat exactly these refractory chronic neurovascular headache patients. The ground-breaking dual-site stimulation targets both the front and back of the head. In ongoing first-in-human studies, PRIMUS has demonstrated a 98.5% effectiveness in reducing the frequency of the debilitating headache attacks (100% patient response rate). PRIMUS advanced design, with a lead of only 0.1 mm and no large implanted battery, significantly mitigates the risks of systemic side effects (0% device-related events reported). This in contrast to existing and competitive neuromodulation devices that are incompatible with the intricate anatomy of the head, placing a heavy and stigmatising burden on patients with severe device-related adverse events such as skin erosion and lead displacement.

Using EIC support, Salvia will fund the clinical pivotal trial, regulatory approval and go-to-market for refractory chronic cluster headache. This strategic approach aims to prioritise the severe, yet comparatively rare, cluster headache indication while simultaneously maintaining a strong commitment to the much larger chronic migraine market worth 109B and heavily supported by our investors. By leveraging the positive outcomes for refractory chronic cluster headache, Salvia aims to convince the key partners, neurologists, to facilitate an expedited market access and penetration, in particular for the large refractory chronic migraine market segment. As such, reaching the full commercial potential of our product driven by its disruptive technology, we aim for market launch in Europe and the USA in 2026 and accelerated yet sustainable company growth followed by a an IPO in 2027.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2023-ACCELERATOR-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

SALVIA BIOELECTRONICS BV
Contributo netto dell'UE
€ 2 499 999,00
Indirizzo
HIGH TECH CAMPUS 37
5656 AE Eindhoven
Paesi Bassi
PMI
Sì
Regione
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 3 727 218,75